acCELLerate, a manufacturer of assay-ready frozen cells, has established an agreement with ATCC, a global biological resource and standards organization, under which acCELLerate will produce custom cell banks from ATCC cell lines for research clients in the pharmaceutical and biotechnology industry.

This collaboration combines ATCC’s portfolio of high-quality, authenticated cell lines with acCELLerate’s expertise in cryopreservation and its capabilities for large scale cell banking. Researchers will gain access to customized Master, Working, and assay ready instaCELL Banks manufactured under acCELLerate’s stringent good cell culture practice to free in-house resources and increase assay reproducibility.

“Our custom cell banks and assay ready instaCELLs support discovery, preclinical development, and QC bioassays,” said Dr. Oliver Wehmeier, Managing Director at acCELLerate. “We can now provide our clients with easy access to ATCC’s unparalleled portfolio of authenticated cell lines for their research. Together with ATCC we are facilitating global research and development of new pharmaceuticals.”

“Authenticated and reproducible lines are the foundation of reliable research that leads to new therapies,” said Dr. Ruth Cheng, President and CEO at ATCC. “Combining acCELLerate’s expertise with ATCC’s authenticated cell lines accelerates the path from discovery to development for biopharma innovators.”